Details for New Drug Application (NDA): 214773
✉ Email this page to a colleague
NDA 214773 describes SILDENAFIL CITRATE, which is a drug marketed by Ajanta Pharma Ltd, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Granules, Hetero Labs Ltd V, Invagen Pharms, Lupin Ltd, MSN, Novitium Pharma, Somerset Theraps Llc, Taro, Teva Pharms Usa, Tris Pharma Inc, Zydus Lifesciences, Eugia Pharma, Actavis Grp Ptc, Amneal Pharms Ny, Apotex Corp, Appco, Cadila Pharms Ltd, Chartwell Rx, Macleods Pharms Ltd, Mylan, Mylan Pharms Inc, Perrigo R And D, Reyoung, Rubicon, Sunshine, Teva, Teva Pharms, Torrent, Torrent Pharms Ltd, Umedica, and Watson Labs Inc, and is included in forty-seven NDAs. It is available from sixty-six suppliers. Additional details are available on the SILDENAFIL CITRATE profile page.
The generic ingredient in SILDENAFIL CITRATE is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
The generic ingredient in SILDENAFIL CITRATE is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
Summary for 214773
| Tradename: | SILDENAFIL CITRATE |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | sildenafil citrate |
| Patents: | 0 |
Pharmacology for NDA: 214773
| Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 214773
Suppliers and Packaging for NDA: 214773
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SILDENAFIL CITRATE | sildenafil citrate | FOR SUSPENSION;ORAL | 214773 | ANDA | Aurobindo Pharma Limited | 59651-420 | 59651-420-11 | 1 BOTTLE in 1 CARTON (59651-420-11) / 112 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 10MG BASE/ML | ||||
| Approval Date: | Dec 23, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
